Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

2013 trends

- PMLiVE

FDA approved 44 new drugs in 2014

AstraZeneca leads pharma success with four approvals, but Bayer had a year to forget  

- PMLiVE

NICE rejects pancreatic cancer regimen over cost concerns

Charity says draft decision to deny Abraxane/Gemzar combo is a ‘backwards step’ for the NHS pricing body

- PMLiVE

Angelini to market Ariad’s Iclusig in Eastern Europe

Comes after leukaemia drug passes EMA safety review

- PMLiVE

Dendreon to go to auction without initial bidder

A selection for a bidder wanting to pay the minimum price has not been made

- PMLiVE

Japan first to approve Novartis psoriasis drug Cosentyx

Becomes first company to gain approval for an interleukin-17 inhibitor

- PMLiVE

Pfizer’s Dr Simon Campbell recognised in UK’s New Year Honours

Recipients also include NICE’s Professor Carole Longson

- PMLiVE

Turkey: A growing pharma market with huge potential

The Turkish biopharma market offers many opportunities - if it can overcome its sustainability challenge

- PMLiVE

Celgene promotes senior EMEA figures

Marie-France Tschudin and Stefano Portolano take on new roles

- PMLiVE

FDA approval for Novo Nordisk’s obesity shot

New formulation of diabetes drug Victoza will be marketed as Saxenda

- PMLiVE

EMA picks projects for adaptive licensing project

Begins discussions on how the model will be implemented in practice

Astellas forges $675m muscle alliance with Cytokinetics

Extendscollaboration to include neuromuscular diseases

NICE rejection of three ovarian cancer drugs stands

Agency will still not recommend Gemzar, Hycamtin and Yondelis for the disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links